Evidence map›Paper›PMID 40118915›Full record

ArticleNPJ vaccines2025

Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.

Jinpan Hu, Zijing Jia, Meng Wang, Lingling Nie, Wangjun Fu, Qingfeng Zhang, Haiyang Qin, Jianhui Nie, Xiaoyu Xu, Lingjie Xu and 9 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Jinpan Hu *National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China.
Zijing Jia *CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China.
Meng WangDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.
Lingling NieDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.
Wangjun FuCAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China.
Qingfeng ZhangDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.
Haiyang QinDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.
Jianhui NieDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.
Xiaoyu XuVazyme Biotech Co. Ltd, 210000, Nanjing, China.
Lingjie XuVazyme Biotech Co. Ltd, 210000, Nanjing, China.
Fengze WangVazyme Biotech Co. Ltd, 210000, Nanjing, China.
Yingping ChenDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.
Bo XingDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.
Tao LiDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.
Danfeng LiGuangxi Institute for Drug Control, Nanning, 530021, China.
Shaowei LiNational Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China.ORCID http://orcid.org/0000-0002-3374-1038
Ningshao XiaNational Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.ORCID http://orcid.org/0000-0003-0179-5266
Xiangxi WangCAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China. xiangxi@ibp.ac.cn.
Weijin HuangNational Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China. huangweijin@nifdc.org.cn.ORCID http://orcid.org/0000-0002-4246-8889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several human papillomavirus (HPV) L1-based virus-like particle (VLP) vaccines are in development to meet future global vaccination needs. Type-specific monoclonal antibodies with good reactivity to all types of vaccines are urgently needed to evaluate vaccine potency. In this study, binding activity, neutralizing activity, conformational sensitivity, immunodominance in human serum, and versatility were compared among antibodies. A broad-spectrum binding antibody (C4-F5-127) was selected as the capture antibody; four type-specific neutralizing antibodies (6-F5-77, 11-F5-187, 16-F5-196, and 18-F5-203) were selected as detection antibodies for HPV6, 11, 16, and 18, respectively. These antibodies formed a standardized and universal in vitro relative potency (IVRP) assay kit. High-resolution cryo-electron microscopy (cryo-EM) structures of HPV6-6-F5-77, HPV11-11-F5-187, HPV16-16-F5-196 and HPV18-18-F5-203 complexes define the location and nature of epitopes, revealing serotype specific binding modes and neutralization mechanisms. The IVRP results were correlated with potency data from mouse models, offering an efficient alternative to in vivo potency experiments.

Identifiers

PMID40118915
PMCPMC11928608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.